GILD vs. GKOS: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at GILD and GKOS, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
GILD dominates in value with a market cap of 134.92 billion USD, eclipsing GKOS’s 5.43 billion USD by roughly 24.84×.
GKOS carries a higher beta at 0.83, indicating it’s more sensitive to market moves, while GILD remains steadier at 0.28.
| Symbol | GILD | GKOS |
|---|---|---|
| Company Name | Gilead Sciences, Inc. | Glaukos Corporation |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Medical - Devices |
| CEO | Mr. Daniel P. O'Day | Mr. Thomas William Burns |
| Price | 108.46 USD | 95.045 USD |
| Market Cap | 134.92 billion USD | 5.43 billion USD |
| Beta | 0.28 | 0.83 |
| Exchange | NASDAQ | NYSE |
| IPO Date | January 22, 1992 | June 25, 2015 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of GILD and GKOS over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of GILD and GKOS based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- GKOS shows a negative P/E of -43.52, highlighting a year of losses, whereas GILD at 22.66 trades on solid profitability.
- GKOS shows a negative forward PEG of -2.45, signaling expected earnings contraction, while GILD at 3.19 maintains analysts’ projections for stable or improved profits.
- GKOS reports a negative Price-to-Free Cash Flow ratio of -102.01, showing a cash flow shortfall that could threaten its operational sustainability, while GILD at 13.71 maintains positive cash flow.
| Symbol | GILD | GKOS |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 22.66 | -43.52 |
| Forward PEG Ratio (TTM) | 3.19 | -2.45 |
| Price-to-Sales Ratio (P/S, TTM) | 4.70 | 13.43 |
| Price-to-Book Ratio (P/B, TTM) | 7.05 | 7.05 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 13.71 | -102.01 |
| EV-to-EBITDA (TTM) | 14.36 | -67.50 |
| EV-to-Sales (TTM) | 5.29 | 13.40 |
| EV-to-Free Cash Flow (TTM) | 15.44 | -101.85 |
Dividend Comparison
GILD delivers a 2.86% dividend yield, blending income with growth, whereas GKOS appears to retain its profits, possibly to fund operations, R&D, or other growth initiatives.
| Symbol | GILD | GKOS |
|---|---|---|
| Dividend Yield (TTM) | 2.86% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of GILD and GKOS, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- GILD meets its interest obligations (ratio 8.35). In stark contrast, GKOS’s negative ratio (-13.09) means its operating earnings (EBIT) don’t cover basic operations, let alone interest, signaling serious financial trouble.
| Symbol | GILD | GKOS |
|---|---|---|
| Current Ratio (TTM) | 1.37 | 6.49 |
| Quick Ratio (TTM) | 1.23 | 5.62 |
| Debt-to-Equity Ratio (TTM) | 1.30 | 0.14 |
| Interest Coverage Ratio (TTM) | 8.35 | -13.09 |